How has been the historical performance of Genpharmasec?

Answer:The historical performance of Genpharmasec shows a mixed trend over the past three years, with notable fluctuations in revenue and profit metrics.

Breakdown:
Genpharmasec's net sales have increased from 25.52 Cr in Mar'23 to 30.41 Cr in Mar'24, and further to 33.72 Cr in Mar'25, indicating a steady growth in total operating income. The total expenditure has also risen, from 25.26 Cr in Mar'23 to 30.36 Cr in Mar'24, and 33.66 Cr in Mar'25, reflecting increased costs in purchases and employee expenses. Operating profit, however, has shown variability, with a peak of 0.36 Cr in Mar'23, dropping to 0.05 Cr in Mar'24, and slightly recovering to 0.06 Cr in Mar'25. Profit before tax improved significantly from 0.28 Cr in Mar'23 to 1.88 Cr in Mar'25, while profit after tax showed a recovery from a loss of 0.17 Cr in Mar'24 to a profit of 1.23 Cr in Mar'25. The company's total assets have increased from 19.03 Cr in Mar'23 to 79.43 Cr in Mar'25, with total liabilities also rising from 19.03 Cr to 79.43 Cr in the same period. Cash flow from operating activities improved from -3.00 Cr in Mar'23 to 2.00 Cr in Mar'25, although the net cash outflow was -13.00 Cr in Mar'25, down from a net inflow of 16.00 Cr in Mar'24. Overall, while Genpharmasec has shown growth in sales and profit recovery, it faces challenges in managing expenses and cash flow.